Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre A, Bachet J, Boige V, Cayre A, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre A, Bachet J, Boige V, Cayre A, et al.
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Cancer Survival Rate Increasing  
  • The 5-year survival rate for prostate cancer has increased from 67% to nearly 100% over the past 20 years.  
  • Since 1975, the five year survival rate for breast cancer patients has increased by 40 percent.  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • Death rates from breast cancer have steadily decreased in women since 1990. This decrease represents progress in both early detection and improved treatment.